Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men.

ABSTRACT:

Introduction

Programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1)-targeted immunotherapies have become a new mode of treatment for several tumours; however, there is limited evidence on the expression and prognostic value of PD-1/PD-L1 in prostate cancer, especially in African men.

Methods

Plasma concentrations of PD-L1/PD-1 were assessed using enzyme-linked immunosorbent assay in patients with prostate cancer and normal healthy controls at the Uganda Cancer Institute. The associations between plasma PD-L1/PD-1 concentration levels and serum prostate-specific antigen (PSA) levels, Gleason scores, age, and body mass index (BMI) were determined.

Results

We found significant differences in the median plasma concentrations of PD-L1 and PD-1 immune checkpoint molecu

SUBMITTER: Katongole P 

PROVIDER: S-EPMC9098749 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature